Top 5 Oncology Articles in 2023

To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year

This month's episode of the Meet the Board podcast features a new member of our editorial advisory board, Marci J. Chodroff, MD, FACP, vice president of Medical Affairs at Magellan Rx Management, a Prime Therapeutics company.

But the waivers that allow for coverage of tele-health expire at the end the year. Several bills have been put forth to extend coverage.

MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!

The authors of an article about relatively low biosimilar use by people with inflammatory bowel disease have suggestions for how to mitigage the nocebo effect.